Bernard joined Omega Funds in 2020. He has extensive experience in the life sciences and biotech industry, marked by a number of successful transactions involving financings and M&A. Bernard currently serves on the Board of Directors of EyeBio, Endeavor BioMedicines, Lexeo Therapeutics, Upstream Bio and Vanqua Bio.
Bernard previously served as SVP and Managing Director at Sanofi Ventures, having first joined Sanofi in 2010 as Vice President, Deputy Global Head, Business Development. Over his 7-year tenure, Sanofi Ventures invested in 28 new companies and generated 14 exits (12 NASDAQ IPOs, 1 trade sale and 1 option deal).
Prior to Sanofi, Bernard held CEO, CFO and other leadership roles at Fovea Pharmaceuticals (which was sold to Sanofi in 2009 in a $540 million cash transaction), Neurotech Pharmaceuticals, Transgene (which successfully raised $100 million in a 1998 IPO on the NASDAQ/EuroNext) and Institut Mérieux (now Sanofi Pasteur).
Bernard received his Executive MBA from The Wharton School of the University of Pennsylvania and his MSc in Management from Emlyon Business School.
